Warring with ex-CEO, options shrinking, Aeterna Zentaris turns to a strategic review
After jettisoning its failed lead therapy and confronting its ex-CEO and general counsel with allegations that they were trying to slip themselves the old, lead failed therapy, Aeterna Zentaris $AEZS says it’s time to engage in a strategic review.
Among the options on the table are reviewing the biotech’s business strategy as well as management and the board.
Perhaps disheartening to investors who have stuck with the Charleston, SC –based company through thick and thin, the release out Tuesday afternoon misspelled Macrilen, their only asset of any value.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.